Metraipolis › archive › dc_ee4f0d0448c8

Cost-effectiveness of leveraging long-acting injectable cabotegravir to expand PrEP coverage among MSM in two contrasting North American cities — Europe PMC PMID:41549755

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41549755
DOI
10.1002/jia2.70061
License (as archived)
solo-consultazione
Archived
2026-11-07T04:30:40.437Z
SHA-256 of the archived text
1ad4ea8dceb90e168ab59c46b6f2ef07fade9d9b69dd96173e56922d998e5447
Stable URL of this page
https://metraipolis.com/documento/dc_ee4f0d0448c8

How to cite

Cost-effectiveness of leveraging long-acting injectable cabotegravir to expand PrEP coverage among MSM in two contrasting North American cities — Europe PMC PMID:41549755 — Europe PMC (en), https://europepmc.org/article/MED/41549755 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ee4f0d0448c8 (Metraipolis archive dc_ee4f0d0448c8, sha256 1ad4ea8dceb90e168ab59c46b6f2ef07fade9d9b69dd96173e56922d998e5447)
BibTeX
@misc{dcee4f0d0448c8,
  title = {Cost-effectiveness of leveraging long-acting injectable cabotegravir to expand PrEP coverage among MSM in two contrasting North American cities — Europe PMC PMID:41549755},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41549755},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ee4f0d0448c8; sha256 1ad4ea8dceb90e168ab59c46b6f2ef07fade9d9b69dd96173e56922d998e5447},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41549755. Agents can read the archived copy with the MCP tool read_document.